Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

In a remarkable display of market confidence, Verona Pharma (NASDAQ:VRNA)'s stock has surged to an all-time high, reaching a ...

The bullish stance is based on the potential of Verona Pharma's Ohtuvayre™, which is expected to address a substantial total addressable market (TAM) of approximately 8.6 million symptomatic patients ...

A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods gained and the significance of the new drugs and biologics that these ...

The adjustment follows Verona Pharma's announcement of fourth-quarter sales for Ohtuvayre, which totaled approximately $36 million, unaudited. These figures surpassed both Truist Securities' estimate ...